Clinical Trial Update: Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D [Phase 4]

View source ↗

Summary

Phase 4 trial investigating continuous rifaximin with probiotics on gut microbiota in irritable bowel syndrome with diarrhea patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gut Microbiota-related Conditions
• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• Probiotics
• Rifaximin (rifaximin)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: IBS - Irritable Bowel Syndrome, Gut Microbiota | Phase 4 | Status: UNKNOWN